Company news
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A (SSE:600436) news
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 23, 2026: "ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO.…
View Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A →
Press releases & updates
"ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 41st Meeting of the 7th Board of Directors
September 22, 2026
"ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD."Semi-annual Report for 2026
August 28, 2026
"ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of the Company's 2025 Annual Report
July 31, 2026
"ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD."Announcement on Departure of Directors and Senior Management Members
July 29, 2026
"ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD."Announcement on Implementation of Dividend Distribution for 2025
July 23, 2026
"ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD."Announcement on Abnormal Fluctuations in Stock Trading
July 17, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 26, 2026
Announcement on Completion of First Participant Enrollment in the Phase III Clinical Trial of Changji’an Capsules
June 23, 2026
Notice on Convening the 2025 Annual General Meeting
June 2, 2026
Announcement on Progress in Investing in the Regenerative Medicine Fund
May 25, 2026
Announcement on Completion of Implementation of Controlling Shareholder's Share Increase Plan and Results
April 30, 2026
Announcement on Change of Securities Affairs Representative
April 29, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
April 28, 2026
Announcement on Receiving the "Imported Medicinal Materials Approval Document"
April 24, 2026
Announcement on External Investment through Participation in the Establishment of a Private Fund
March 27, 2026
Announcement on Election of Employee Directors for the 7th Board of Directors
March 1, 2026
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
February 11, 2026
Announcement on Completion of 1st Subject Enrollment in Phase Ⅱ Clinical Trials of PZH2107
February 10, 2026
Announcement on Controlling Shareholder Obtaining a Special Loan Commitment Letter for Shareholding Increase
February 4, 2026
Announcement on Completion of 1st Subject Enrollment in Phase I Clinical Trials of PZH2113 Capsules
January 27, 2026
Announcement on Progress in Investment in the CICC Medical Fund
January 19, 2026
Announcement on Completion of 1st Subject Enrollment in Phase II Clinical Trials of Wenfei Dingchuan Capsules
January 13, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
December 9, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
November 20, 2025
Announcement on Progress in Participation in Investment Gaoxin Runxin Fund
October 24, 2025
Announcement on Main Operating Data for the First Three Quarters of 2025
October 17, 2025
Announcement on Participation in Investment CICC Medical Fund and Related Party Transactions
September 28, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
September 23, 2025
Announcement on Resolutions of the 33rd Meeting of the 7th Board of Directors
August 29, 2025
Announcement on the Upgrade of the Company’s Credit Rating
August 22, 2025
Announcement on Change of Directors and Supervisors
August 13, 2025
Announcement on Participation in Investment Gaoxin Runxin Fund and Related Party Transactions
August 6, 2025
Announcement on Implementation of Dividend Distribution for 2024
July 23, 2025
Announcement on Completing Registration of Free Transfer of State-owned Shares
July 3, 2025
Indicative Announcement on Free Transfer of State-owned Shares and Equity Change Reaching 1% for Shareholders with Over 5% Shares
June 23, 2025
Announcement on Resolution of the General Meeting
June 20, 2025
Announcement on Progress of Investment and Participation in Zhaoying Huikang Fund
May 30, 2025
Notice on Convening the 2024 Annual General Meeting
May 29, 2025
Announcement on Attending the Online Collective Reception Day for Investors of Listed Companies in Fujian Jurisdiction in 2025 and the 2024 Annual and Q1 2025 Performance Briefing
April 29, 2025
Announcement on Daily Related Party Transactions in 2024 and Estimated Daily Related Party Transactions in 2025
April 25, 2025
Announcement on Resolutions of the 19th Meeting of the 7th Board of Supervisors
March 31, 2025
Announcement on Receiving Notice of Approval for Drug Clinical Trials
March 24, 2025
Announcement on 2024 Annual Preliminary Earnings Estimate
January 23, 2025
Announcement on Change of Director and Senior Management Members
January 7, 2025
Announcement on Progress of Remuneration for Directors, Supervisors and Senior Management Members
December 30, 2024
Announcement on Progress of Investment in the Establishment of Pien Tze Huang-Yingke Fund
November 27, 2024
Report for Q3 2024
October 18, 2024
Announcement on Implementation of Semi-annual Dividend Distribution in 2024
October 14, 2024
Announcement on the Progress of Investment to Participate in Establishing a Fund
October 7, 2024
Announcement on the Progress of Investment in Establishing a Fund
September 3, 2024